Newly activated UI Cancer Center clinical trials

Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on ClinicalTrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.

https://clinicaltrials.gov/ct2/show/NCT03598257?term=s1706&rank=1

Principal Investigator: Oana Danciu, MD
Sponsor: National Cancer Institute (NCI)

BrainUp: A Phase 1 Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma

This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temazolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)).

During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.

https://clinicaltrials.gov/ct2/show/NCT03011671

Principal Investigator: Martin Kelly Nicholas, MD
Sponsor: University of Chicago

BGB 3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in subjects with relapsed/refractory non-Hodgin follicular lymphoma.

https://clinicaltrials.gov/ct2/show/NCT03332017?term=bgb+3111-212&rank=1

Principal Investigator: John Galvin, MD
Sponsor: BeiGene

Leave a reply

Your email address will not be published. Required fields are marked *